A species of AVIPOXVIRUS, subfamily CHORDOPOXVIRINAE. Canarypox virus vectors are used in vaccine and immunotherapy research.
A genus of the family POXVIRIDAE, subfamily CHORDOPOXVIRINAE, comprising bird poxviruses. The type species is FOWLPOX VIRUS. Transmission is mechanical by ARTHROPODS.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A cell line derived from cultured tumor cells.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Injections introduced directly into localized lesions.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
The relationships of groups of organisms as reflected by their genetic makeup.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Sequential operating programs and data which instruct the functioning of a digital computer.
Genotypic differences observed among individuals in a population.
A class of amino acids characterized by a closed ring structure.
Recording of pertinent information concerning patient's illness or illnesses.
A genus of mosquitoes (CULICIDAE) commonly found in tropical regions. Species of this genus are vectors for ST. LOUIS ENCEPHALITIS as well as many other diseases of man and domestic and wild animals.
A species of FLAVIVIRUS, one of the Japanese encephalitis virus group (ENCEPHALITIS VIRUSES, JAPANESE). It can infect birds and mammals. In humans, it is seen most frequently in Africa, Asia, and Europe presenting as a silent infection or undifferentiated fever (WEST NILE FEVER). The virus appeared in North America for the first time in 1999. It is transmitted mainly by CULEX spp mosquitoes which feed primarily on birds, but it can also be carried by the Asian Tiger mosquito, AEDES albopictus, which feeds mainly on mammals.
A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71)
The development by insects of resistance to insecticides.
Insects that transmit infective organisms from one host to another or from an inanimate reservoir to an animate host.
Warm-blooded VERTEBRATES possessing FEATHERS and belonging to the class Aves.
A family of the order DIPTERA that comprises the mosquitoes. The larval stages are aquatic, and the adults can be recognized by the characteristic WINGS, ANIMAL venation, the scales along the wing veins, and the long proboscis. Many species are of particular medical importance.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
The collective designation of three organizations with common membership: the European Economic Community (Common Market), the European Coal and Steel Community, and the European Atomic Energy Community (Euratom). It was known as the European Community until 1994. It is primarily an economic union with the principal objectives of free movement of goods, capital, and labor. Professional services, social, medical and paramedical, are subsumed under labor. The constituent countries are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, and the United Kingdom. (The World Almanac and Book of Facts 1997, p842)
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.
Laws concerned with manufacturing, dispensing, and marketing of drugs.
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.

Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination. (1/35)

The two main constraints that currently limit a broader usage of T cell therapy against viruses are the delay required to obtain specific T cells and the safety of the selection procedure. In the present work we developed a generally applicable strategy that eliminates the need for APC for timing reasons, and the need for infectious viral strains for safety concerns. As a model, we used the selection of T lymphocytes specific for the immunodominant CMV phosphoprotein pp65. PBMC from healthy seropositive donors were first depleted of IL-2R alpha-chain CD25(+) cells and were then stimulated for 24-96 h with previously defined peptide Ags or with autologous PBMC infected with a canarypox viral vector encoding the total pp65 protein (ALVAC-pp65). Subsequent immunomagnetic purification of newly CD25-expressing cells allowed efficient recovery of T lymphocytes specific for the initial stimuli, i.e., for the already known immunodominant epitope corresponding to the peptides used as a model or for newly defined epitopes corresponding to peptides encoded by the transfected pp65 protein. Importantly, we demonstrated that direct PBMC stimulation allowed recovery not only of CD8(+) memory T lymphocytes, but also of the CD4(+) memory T cells, which are known to be crucial to ensure persistence of adoptively transferred immune memory. Finally, our analysis of pp65-specific T cells led to the identification of several new helper and cytotoxic epitopes. This work thus demonstrates the feasibility of isolating memory T lymphocytes specific for a clinically relevant protein without the need to prepare APC, to use infectious viral strains, or to identify immunodominant epitopes.  (+info)

Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. (2/35)

Since virus-specific CTL play a central role in containing HIV replication, a candidate AIDS vaccine should generate virus-specific CTL responses. In this study, the ability of a recombinant canarypox virus expressing SIV Gag-Pol-Env (ALVAC/SIV gag-pol-env) was assessed for its ability to elicit both dominant and subdominant epitope-specific CTL responses in rhesus monkeys. Following a series of five immunizations, memory CTL responses specific for a dominant Gag epitope could be demonstrated in the peripheral blood of vaccinated monkeys. Memory CTL responses to a subdominant Pol epitope were undetectable in these animals. Following challenge with SIVmac251, the experimentally vaccinated animals developed high frequency CTL responses specific for the dominant Gag epitope that emerged in temporal association with the early containment of viral replication. Interestingly, the experimentally vaccinated, but not the control vaccinated animals, developed CTL responses to the subdominant Pol epitope that were detectable only after containment of early viremia. Thus, recombinant canarypox vaccination elicited low frequency, but durable memory CTL populations. The temporal association of the emergence of the dominant epitope-specific response with early viral containment following challenge suggests that this immune response played a role in the accelerated clearing of early viremia in these animals. The later emerging CTL response specific for the subdominant epitope may contribute to the control of viral replication in the setting of chronic infection.  (+info)

Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. (3/35)

Poxviruses that are attenuated for growth in human cells provide a safe means of HIV antigen expression and are capable of eliciting HIV-specific immune responses, including CD8+ cytotoxic T-lymphocyte (CTL) responses. HIV-1 antigen expression in human cells by attenuated poxvirus vectors may be limited by interferon-mediated host defense mechanisms. To enhance HIV antigen expression in human cells, the vaccinia virus E3L and K3L genes were inserted into a canarypox vector that expresses HIV-1 Gag, Env, and a Nef/Pol polyepitope string. E3L and K3L markedly reduced the activation of the double-stranded RNA-dependent protein kinase, PKR, and led to a significant reduction in apoptosis in HeLa cells. Production and release of HIV-1 antigen in the form of pseudovirions was enhanced in both duration and magnitude by this vector modification. The addition of immunomodulatory genes to attenuated poxviruses represents a novel strategy for enhancing antigen production by live vector HIV vaccine candidates.  (+info)

Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. (4/35)

PURPOSE: The tumor-associated auto-antigen p53 is commonly overexpressed in various types of human cancer, including colorectal cancer. Experiments in preclinical models have shown that it can serve as a target for T-cell-mediated tumor-eradication. The feasibility of a p53-specific therapeutic vaccination was investigated in cancer patients. EXPERIMENTAL DESIGN: A Phase I/II dose-escalation study was performed that evaluated the effect of a recombinant canarypoxvirus (ALVAC) vaccine encoding wild-type human p53 in 15 patients with advanced colorectal cancer. Each group of five patients received three i.v. doses of one-tenth of a dose, one-third of a dose, or 1 dose of the vaccine [1 dose = 1 x 10(7.5) cell culture infectious dosis (CCID)50]. RESULTS: Potent T-cell and IgG antibody responses against the vector component of the ALVAC vaccine were induced in the majority of the patients. Enzyme-linked immunosorbent-spot assay (ELISPOT) analysis of vaccine-induced immunity revealed the presence of IFN-gamma-secreting T cells against both ALVAC and p53, whereas no significant interleukin-4 responses were detected. Vaccine-mediated enhancement of p53-specific T-cell immunity was found in two patients in the highest-vaccine-dose group. CONCLUSIONS: This study demonstrated the feasibility, even in patients with advanced cancer, to elicit immune responses against the ubiquitously expressed tumor-associated auto-antigen p53. Our results form the basis for additional studies that will explore the antitumor capacity of p53 containing multivalent vaccines in cancer patients with limited tumor burden.  (+info)

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. (5/35)

Preclinical data are reported that support a human immunodeficiency virus (HIV) vaccine strategy using recombinant canarypox-HIV vectors (ALVAC-HIV) to load human dendritic cells (DCs) with HIV antigens. Clinical-grade DCs were infected with good manufacturing practice-grade ALVAC-HIV vaccine constructs. ALVAC infection, HIV gene expression, and DC viability and function were monitored by use of immunohistochemistry, flow cytometry, blastogenesis assays, antigen-specific interferon (IFN)-gamma enzyme-linked immunospot assay, and enzyme-linked immunosorbent assay protein detection. The vaccines infected both immature and mature DCs, and intracellular HIV-1 Gag protein was detected within hours. ALVAC-HIV induced DC maturation that was mediated by tumor necrosis factor-alpha and induced DC apoptosis that was directly related to the length of vaccine exposure. Of importance, the infected DCs remained functional in T cell stimulation assays and induced HIV antigen-specific CD8(+) T cell production of IFN-gamma from cells of HIV-1-infected individuals. These data support an ongoing HIV vaccine trial comparing conventional vaccine delivery routes with ex vivo vaccine-loaded autologous DCs for immunogenicity in HIV-1-uninfected volunteers.  (+info)

DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. (6/35)

We studied immune responses to hepatitis C virus (HCV) genes delivered as DNA encoding the entire HCV protein coding genome in two polycistronic plasmids encoding HCV capsid-E1-E2-NS2-NS3 and HCV NS3-NS4-NS5 in HLA-A2.1-transgenic mice. Immune responses to HCV DNA prime and recombinant canarypox virus boost were also studied with the above constructs. At 8 weeks after a canarypox virus boost, the DNA prime/canarypox virus boosting regimen induced potent cellular immune responses to HCV structural and nonstructural proteins on target cells expressing the HLA-A2.1 allele. High frequencies of gamma interferon-secreting cells, as detected by enzyme-linked immunospot assay, were obtained in response to several endogenously expressed HCV proteins. We also observed cytotoxic-T-lymphocyte reactivity in response to endogenously expressed HCV proteins in fresh spleen cells without in vitro expansion. Upon challenge with a recombinant vaccinia virus expressing HCV proteins at 2 months postimmunization, the HCV DNA prime/canarypox virus-immunized mice showed a complete reduction in vaccinia virus titers compared to HCV DNA prime/boost- and mock-immunized controls. Immune responses were still detectable 4 months after canarypox virus boost in immunized mice. Interestingly, at 10 months postimmunization (8 months after canarypox virus boost), the protection in HCV DNA prime/boost-immunized mice against recombinant HCV-vaccinia virus challenge was higher than that observed in HCV DNA prime/canarypox virus boost-immunized mice.  (+info)

Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice. (7/35)

The non-classical major histocompatibility complex class I molecule HLA-G is expressed mainly by extravillous trophoblasts at the materno-foetal interface. HLA-G has been found to bind endogenously processed nonameric peptides but its function as a restriction element for a cytotoxic T cell response to viruses with tropism for trophoblastic cells has never been demonstrated. In this study, candidate viral peptides derived from human cytomegalovirus (HCMV) pp65 (UL83), which stabilized the HLA-G molecule on HLA-G-transfected T2 cells, were identified. The specific anti-pp65 cytotoxic T lymphocyte (CTL) response restricted by HLA-G in triple transgenic mice (HLA-G, human beta2m, human CD8alpha) was then investigated by injection of dendritic cells loaded with synthetic pp65-derived peptides or by infection with canarypox virus expressing pp65. Results showed that CTLs from HLA-G mice have the capacity to kill target cells either infected with recombinant vaccinia viruses expressing pp65 or loaded with specific pp65-derived peptides using HLA-G as an antigen-presenting molecule. It was also demonstrated that these HLA-G-restricted pp65-specific T cells are able to kill the human astrocytoma cell line U373, which was transfected with HLA-G and infected with HCMV. Moreover, using HLA-G tetramers refolded with a synthetic pp65-derived peptide, peptide-specific CD8(+) cells restricted by HLA-G have been detected in vivo. These findings provide the first evidence that HLA-G can select anti-HCMV-restricted CTLs in vivo, although the potency of this cytolytic response is limited (20-25 %). The weak HLA-G-restricted anti-HCMV response is probably due to HLA-G-mediated inhibitory signals on the development of an antiviral CTL response.  (+info)

Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. (8/35)

Since 1987, >10,000 individuals worldwide have received immunizations with human immunodeficiency virus (HIV) preventive vaccine constructs. Many constructs elicit antibodies detected by standard serologic tests (enzyme immunoassays, rapid tests, and Western blots) and result in vaccine recipients' serum being identified as reactive and indicative of HIV infection. To determine the frequency of vaccine-induced HIV antibody among uninfected HIV vaccine trial participants and to identify factors associated with these results, serum samples from HIV-uninfected participants from selected United States phase I/II HIV-1 vaccine trials were tested with 6 serologic screening tests. Reactive specimens were tested by use of Western blot. Overall, 490 serum specimens from 461 vaccine recipients were tested; 100 (20.4%) reacted on at least 1 serologic test, and 65 (13%) were determined to be positive by Western blot. Canarypox or vaccinia vaccine recipients' serum with or without HIV envelope glycoprotein (gp120 or gp160) boosts accounted for all positive Western blot results; no positive Western blot results were obtained from gp120 subunit recipients. The potential for vaccine recipients being misclassified as HIV infected increased with vaccine complexity.  (+info)

Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) [ALVAC CEA] or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With Surgically Incurable Melanoma ...
In this thesis, two different vaccines were evaluated as adjuvant therapy for patients with colorectal cancer. The ability of the two candidate vaccines to generate antigen-specific cellular and humoral responses, respectively, was studied. The effectiveness of granulocyte colony stimulating factor (GM-CSF) as a cytokine adjuvant to augment the immune response was also examined.. The first vaccination strategy involved immunization with the recombinant tumor-associated protein, carcinoembryonic antigen (CEA). Recombinant CEA was administered at 4 different dose levels 7 times during one year. Peripheral blood samples were regularly analyzed during 36 months. This vaccination regimen induced a strong immunoglobulin 1 (IgG1) and IgG4 response, a moderate IgG2 response and a weak IgG3 response against CEA. GM-CSF markedly augmented the effect on IgG1 and IgG4 as well as the T cell response. In contrast, dose of rCEA had no or modest effect on induced immune responses. The response gradually ...
One of the earliest observations in the HIV epidemic was the demonstration of HIV infection at mucosal surfaces of cells in the genital tract. These data suggest that priming of immune defenses of viral infected cells may be an important component in the strategy of developing an effective HIV vaccine. Direct immunization of relevant mucosal surfaces with a vectored vaccine may stimulate mucosal immunity. The ALVAC-HIV vCP205 immunogen is constructed from a live recombinant canarypox vector that has a good safety profile in volunteers and should allow mucosal induction of immunity.. This randomized, double-blind trial evaluates the safety of and immune response to vaccination with ALVAC-HIV vCP205 given at 0, 1, 3, and 6 months. Patients are randomly assigned to 1 of 7 drug administration routes as follows:. Group A: Intramuscular Group B: Oral Group C: Intranasal Group D: Intrarectal Group E: Intravaginal Group F: Intranasal/intramuscular Group G: Intrarectal/intramuscular Twelve patients are ...
Mother-to-child transmission (MTCT) of HIV can be caused either by perinatal transmission of HIV or by breastfeeding, a common practice in poorer regions of the world. HIV preventive vaccines are currently under investigation as potential solutions to worldwide MTCT of HIV. This study will evaluate the safety and immunogenicity of an HIV-1 vaccine, ALVAC-HIV vCP1521, in infants born to HIV-1 infected mothers in Uganda. The vaccine is a preparation of a live attenuated recombinant canarypox virus, encoding HIV clades B and E envelope proteins. This study will be conducted at Mulago Hospital in Uganda.. Mothers will enroll in this study during their third trimesters of pregnancy. During screening, mothers will undergo medical history assessment, a physical exam, and blood collection. After delivery and prior to infant enrollment, mothers will have another physical exam; mothers and their infants will be accompanied home by a home visitor who will document contact information.. Infants will be ...
The shock-and-kill method combines latency reversal agents such as histone deacetylase inhibitors and toll-like receptor (TLR) agonists to induce HIV-1 transcription followed by ART, therapeutic vaccines, and/or broadly neutralizing antibodies (bNAbs) to decrease the latent reservoir. This process of reac-tivation is then followed by immunomodulation with agents such as therapeutic vaccines and/or bNAbs. The aim of therapeutic vaccines (such as the modi-fied vaccinia Ankara B and the recombinant canarypox virus) is to elicit an antigenic immune response to suppress viral replication in the absence ofART. Broadly neutralizing antibodies (such as VRC01 and 3BNC117) induce hostimmunity by targeting specific epitopes of HIV.. I am are also working on emerging strategies and evolving science regarding genetic modification have unlocked new approaches for HIV cure research. These approaches include using CRISPR and CAR T-cell technology. CRISPR enables DNA cleavage to occur prior to proviral ...
Viral vectors derived from different virus families, including poxvirus (canarypox virus vector ALVAC) and adenovirus (human Ad5 vector), have been widely used in vaccine development for a range of human diseases including HIV/AIDS. Less is known about the mechanisms underlying the host innate response to these vectors. Increasing evidence from clinical vaccine trials testing different viral vectors has suggested the importance of understanding basic elements of host-viral vector interactions. In this study, we investigated the innate interactions of APCs with two commonly used HIV vaccine vectors, ALVAC and Ad5, and identified AIM2 as an innate sensor for ALVAC, triggering strong inflammasome activation in both human and mouse APCs ...
موقعي كه زخم آبله در حنجره ايجاد مي شود، نفس كشيدن پرنده مشكل مي‌گردد. اغلب نفس نفس مي زند. اين حالت همزمان با ورود ويروس در خون ايجاد مي شود ولي اگر شدت ويروس و يا مقدار آن زياد باشد پرنده تلف مي‌گردد.. ترکیبات:. -ویال A (ویال جهت درمان موضعی):. Chloramphenicol…………… 4g. Excipient q.s. ………………100ml. -ویال B (ویال جهت درمان خوراکی):. Chloramphenicol…………….. 5,4g. Excipient q.s. ………………100ml. حیوانات هدف:. قناری، فنچ، طوطی، کبوتر و سایر پرندگان زینتی. میزان مصرف:. - تجویز در آب آشامیدنی ( ویال B) :. درمان می بایست در اولین زمان ممکن و از زمانی که احتمال بروز این بیماری وجود دارد، آغاز گردد.. میزان ...
IL-12 gene therapy may induce antitumor effects and potentially avoid the systemic toxicity associated with IL-12 protein immunotherapy (5, 27, 46-48). Prior studies have tested direct transfer of IL-12 cDNA into tumor, either using certain tumor cells engineered in vitro to release IL-12 (3, 30, 48) or using direct intratumoral injection of an adenovirus expressing IL-12 DNA (34) or a Canarypox virus expressing IL-12 vector (49). In addition, particle-mediated transfer of IL-12 cDNA was effectively used to treat murine tumors (2, 5, 28). All of these methods could inhibit tumor growth and induce antitumor immunity. Direct intratumoral injection of IL-12 cDNA, either naked or in complex with a liposome formulation, may provide an alternative, simpler, and safer gene transfer method compared with localized or systemic viral gene vector therapy. Liposomes have been used previously as a delivery agent incorporating nonviral plasmid vectors encoding other cytokine genes, including IL-2 and IL-4, to ...
Then the Thai government did an amazing thing: it acknowledged the importance of HIV, identified the source and instituted a prevention program, enforcing condom use in brothels. The impact was dramatic. Rates of infection declined precipitously and prevalence in sentinel populations fell. The epidemic was changing before a vaccine could be brought to the field. As incidence dropped, the trial had to become larger and compromises had to be introduced.. Initial plans called for optimizing both cellular and humoral HIV-specific responses using a prime-boost approach: a single prime (ALVAC-HIV, a CRF01-specific canarypox vaccine) was to be tested with three different boosts (subunit vaccines) in phase II trials from which the best regimen would be chosen for the Phase III trial. Shortly before the Phase II trials were complete, two of the manufacturers withdrew their products. The ALVAC-HIV + AIDSVAX B/E combination, the only regimen remaining, passed immunogenicity criteria for advancement to ...
Advanced ovarian cancer has the highest mortality rate among patients with cancers of the female reproductive system in the United States. Existing therapies fo...
Sanofi Pasteur announced the results of a Phase 3 trial with its HIV prime vaccine, ALVAC HIV (recombinant canarypox vCP1521) in combination with the booster AidsVax B/E (recombinant gp120 vaccine, from VaxGen).
A number of immune-based therapies continues to be developed to be able to boost or induce protective Compact disc8+ T cell responses to be able to control HIV replication. [10]. Sadly, these fresh vaccines and therapies usually do not deliver the expected success yet. For example, Autran et al. reported considerably elevated viral lots in chronically contaminated patients set alongside the placebo group after discontinuation of therapy pursuing immunization with vCP1452, the HIV-recombinant canarypox vaccine (ALVAC-HIV) [11]. Incredibly, individuals receiving more dosages from the vaccine rapidly required treatment resumption more. Analysis of the results immensely important how the vaccine didnt elicit protecting HIV-specific Compact disc8+ T cell reactions [12]. Moreover, primarily induction of triggered Compact disc4+ T cell reactions was proven in vaccines, which increased target cell availability and rendered patients even more vunerable to Volasertib distributor disease progression ...
Recommended Readings. Dhodapkar MV; Sznol M; Wang D, et al. 2010. Early development of CDX-1401, a novel vaccine targeting NY-ESO-1 to the dendritic cel receptor DEC-205. Journal of Immunotherapy. 33(8):895-896 Request Article from Markus Library. Wanialla CN; Faul EJ; Gomme EA, et al. 2010. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine. 29(1):130-140. Fiorentini S; Giagulli C; Caccuri F, et al. 2010. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacology & Therapeutics. 128(3):433-444 Request Article from Markus Library.. De Groot A; Buhlmann J; Weber C, et al. 2010. De-Tolerization of anti-DEC-205 for HIV vaccine delivery. (abstract only) AIDS Research and Human Retroviruses. 26(10):A135-A136. Ahlers, JD; and IM Belyakov. 2009. Strategies for optimizing targeting and delivery of mucosal HIV vaccines. European Journal of Immunology. ...
SnuggleScents Essentials is a collection of aromas that are great for calming nerves and soothing nasal passages. The Essentials is tailored for new
The inability of current HIV vaccine regimens to generate a broad neutralizing antibody response against primary isolates leaves a major gap in our vaccine armamentarium. There is broad consensus that generation of such antibodies at high titer in vaccinated individuals in combination with vectors that elicit strong cellular immune responses is desirable. Immunogens that recreate the native, trimeric envelope glycoprotein structure on a lipid membrane have the potential to avoid generating undesirable antibodies directed against epitopes on gp120 that are not exposed on native virions. Whether antibodies raised by such membrane-bound primary isolate Env complexes can elicit strong neutralizing antibody responses remains to be determined.. The primary goal of this study was to define the ability of Gag-Env pseudovirions to generate antibodies capable of neutralizing primary HIV-1 isolates. Pseudovirions represent one means of presenting the Env glycoprotein complex in its native form. One of the ...
A chemiluminescence study showed that hepatitis B virus (HBV) and hepatitis C virus (HCV) DNA amplicons are capable of induced radiation when exposed to electromagnetic fields (EMFs) that range from...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Clortermine (Voranil) was developed by Ciba in the 1960s[1] and is an anorectic drug of the amphetamine class.[2] It is the 2-chloro analogue of the better known appetite suppressant phentermine, and is the 2-chloro positional isomer of chlorphentermine. Clortermine produces very low rates of self-administration in animals similarly to chlorphentermine,[3] and as a result it likely does not act on dopamine. Instead, it may act as a serotonin and/or norepinephrine releasing agent.[citation needed] ...
Download the PDF version here. WHO WE ARE AND WHAT WE BELIEVE IN. We, 60 activists, advocates, and representatives from youth-led, youth-serving, and youth-allied organisations from diverse social movements in Asia and the Pacific region, came together in Bangkok to call for sustainable solutions to eradicate poverty and promote prosperity in the region through an intersectional analysis and participatory approach. A multidimensional perspective on poverty necessitates addressing not only economic concerns, but also environmental sustainability, as well as social dimensions-such as youth leadership and empowerment, gender equality, health, education, freedom from violence, right to information and technology, and human rights, including of young people and women who are poor, people of diverse sexual orientation and gender identities and expressions, people with all forms of disability, people living with and affected by HIV, ethnic minorities and indigenous peoples, people living in remote, ...
"Characterization of canarypox-like viruses infecting endemic birds in the Galápagos Islands". Journal of Wildlife Diseases. 41 ...
C22orf25 is also xenologous to T10 like proteins in the Fowlpox Virus and Canarypox Virus. The gene coding for C22orf25 is ... of the C22orf25 gene that are evolutionarily conserved in the Animalia and Plantae kingdoms as well as the Canarypox Virus ...
A strain of canarypox virus modified to carry feline interleukin-2 is used to treat cats with fibrosarcoma. Retroviruses are ... Tobacco mosaic virus (TMV) is the first virus to be discovered. Viral vectors based on tobacco mosaic virus include those of ... Adeno-associated virus (AAV) is a small virus that infects humans and some other primate species. AAV is not currently known to ... Such a virus can efficiently infect cells but, once the infection has taken place, requires a helper virus to provide the ...
... is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) ...
The ALVAC vector is an inert form of canarypox, which is a bird virus which cannot cause disease or replicate in humans. ... Dolgin, Elie (2009-09-24). "Vaccine protects against HIV virus". Nature News. doi:10.1038/news.2009.947. Rerks-Ngarm, S.; ... the vaccine regimen had no effect on the amount of virus in the blood of volunteers who became HIV-infected during the study. ... "Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in ...
"Immunization of Experimental Dogs With Salivary Proteins From Lutzomyia Longipalpis, Using DNA and Recombinant Canarypox Virus ...
His own research was on the canarypox virus, which he used in developing a chick embryo assay for the isolation and ... He made a vaccine for the Q virus He was awarded the Beit Memorial Fellowship by the Lister Institute in 1926; this gave him ... He brought back a set of viruses from the National Institute to begin the basis of research in Melbourne. When Burnet returned ... Following his productive work in London, the Rockefeller Institute agreed to fund a new virus research laboratory in Melbourne ...
... canarypox virus MeSH B04.280.650.160.100.300 - fowlpox virus MeSH B04.280.650.160.150 - capripoxvirus MeSH B04.280.650.160. ... yellow fever virus MeSH B04.820.250.400 - gb virus a MeSH B04.820.250.405 - gb virus b MeSH B04.820.250.410 - GB virus C MeSH ... canarypox virus MeSH B04.909.204.783.160.100.300 - fowlpox virus MeSH B04.909.204.783.160.150 - capripoxvirus MeSH B04.909. ... yellow fever virus MeSH B04.909.777.310.400 - gb virus a MeSH B04.909.777.310.405 - gb virus b MeSH B04.909.777.310.410 - GB ...
... that uses genetic elements of several different HIV strains encapsulated in a harmless canarypox virus vector. AIDSVAX B/E, ... effectively disabling the virus so that it could not bind to or invade susceptible cells. Then, another group, infected with a ... from a strain of the virus, MN, known at the time to infect people in the United States and Europe. The vaccine was designed to ...
... feline rhinotracheitis virus QI06AD06 Feline parapox virus QI06AD07 Feline leukaemia recombinant live canarypox virus QI06AD08 ... QI06AA01 Feline leukaemia virus QI06AA02 Feline panleukopenia virus/parvovirus QI06AA03 Rabies virus + feline rhinotracheitis ... live feline panleucopenia virus / parvovirus + live chlamydia + feline leukaemia recombinant live canarypox virus Empty group ... recombinant live canarypox virus QI06AE01 Chlamydia QI06AE02 Bordetella QI06AF01 Feline panleucopenia virus/parvovirus + feline ...
L03AX18 Cridanimod L03AX19 Dasiprotimut-T L03AX21 Elapegademase QL03AX90 Feline interleukin-2 recombinant canarypox virus ( ...
Another study to test whether the ALVAC recombinant canarypox virus could prime the immune system in cats was performed. This ... The specific virus that they get is H5N1, which is a subtype of Avian Influenza. In order to get the virus, cats need to be in ... Two of the main organs that the virus affects are the lungs and liver. The H5N1 virus has been found in China, Thailand, ... where three stray cats were found to be either dying or dead during the peak time of the virus outbreak. Because the virus ...
Juncopox virus, Mynahpox virus, Psittacinepox virus, Sparrowpox virus, Starlingpox virus, Pigeonpox virus, Turkeypox virus and ... Canarypox virus (CNPV) is a member of the Poxviridae family. Canarypox viruses, as with other bird pox viruses, are in the ... Canarypox virus (CNPV) is an Avipoxvirus and etiologic agent of canarypox, a disease of wild and captive birds that can cause ... leukaemia virus, HIV and cancers; such as melanoma and colorectal cancers. A strain of canarypox virus modified to carry feline ...
They were then boosted with a recombinant canarypox virus encoding all four antigens (ALVAC-4). Immunized monkeys developed ... They altered the DNA of cowpox virus by inserting a gene from other viruses (namely Herpes simplex virus, hepatitis B and ... The Sindbis virus and Semliki Forest virus have been used to build recombinant alphavirus replicons. Unlike conventional DNA ... activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus ...
... an adjuvanted killed virus noninfectious vaccine and a nonadjuvanted canarypox virus-vectored recombinant infectious vaccine ( ... Feline leukemia virus (FeLV) is an RNA virus in the subfamily Oncovirinae belonging to the Retroviridae family. The virus ... Merial produces a recombinant vaccine consisting of canarypox virus carrying FeLV gag and env genes (sold as PUREVAX FeLV in ... Once the virus has entered the cat, there are six stages to a FeLV infection[citation needed]: Stage One: The virus enters the ...
Juncopox virus, Mynahpox virus, Psittacinepox virus, Sparrowpox virus, Starlingpox virus, Pigeonpox virus, Canarypox virus and ... but most of our knowledge comes from the study of fowlpox virus and canarypox virus as they are the only species with full ... Turkeypox virus is a virus of the family Poxviridae and the genus Avipoxvirus that causes turkeypox. It is one of the most ... Turkeypox virus, like other Avipoxviruses, is an enveloped, double-stranded DNA virus with a large, linear genome of ...
... may refer to: Chickenpox, a highly contagious illness caused by primary infection with varicella zoster virus (VZV) Plum ... pox, the most devastating viral disease of stone fruit from the genus Prunus Poxviruses Canarypox, a disease of wild and ... caused by either of two virus variants, Variola major and Variola minor Hemorrhagic smallpox, a severe manifestation of ...
African horse sickness virus, rabbit hemorrhagic disease virus, herpes simplex virus, hepatitis C virus, bluetongue virus, ... A prime-dose regimen with canarypox ALVAC-HIV (vCP1521) vaccine and HIV-1 gp120 AIDSVAX B/E was found to be safe, well ... canine distemper virus, feline leukemia virus, feline immunodeficiency virus, equine influenza virus, equine herpes virus, ... Vaccines against several pathogens including avian influenza virus, Newcastle disease virus, cytomegalovirus, ...
February 2007). "Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune ... pdm09-like virus an A/Kansas/14/2017 (H3N2)-like virus a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) a B/Phuket/ ... pdm09-like virus an A/Hong Kong/2671/2019 (H3N2)-like virus a B/Washington/02/2019 (B/Victoria lineage)-like virus a B/Phuket/ ... pdm09-like virus an A/Hong Kong/45/2019 (H3N2)-like virus a B/Washington/02/2019 (B/Victoria lineage)-like virus a B/Phuket/ ...
... Canarypox virus Flamingopox virus Fowlpox virus Juncopox virus Mynahpox virus Penguinpox virus Pigeonpox virus ... Psittacinepox virus Quailpox virus Sparrowpox virus Starlingpox virus Turkeypox virus Viruses in Avipoxvirus are enveloped. ... Vaccines have been developed from some species of the virus, such as Fowlpox, Canarypox, Pigeonpox, and Quailpox to help ... Avian pox viruses appear to be family or order specific, that is, a pox virus infecting gamebirds is not likely to infect ...
Canarypox virus Fowlpox virus Juncopox virus Mynahpox virus Pigeonpox virus Psittacinepox virus Quailpox virus Sparrowpox virus ... Camelpox virus Cowpox virus Ectromelia virus Monkeypox virus Raccoonpox virus Skunkpox virus Taterapox virus Vaccinia virus ... Nile crocodilepox virus Genus: Leporipoxvirus Hare fibroma virus Myxoma virus Rabbit fibroma virus Squirrel fibroma virus Genus ... Starlingpox virus Turkeypox virus Genus: Capripoxvirus Goatpox virus Lumpy skin disease virus Sheeppox virus Genus: ...
Empty group QI01KA01 Pacheco's virus/herpesvirus Empty group Empty group QI01KD01 Canary pox virus QI01KD02 Pacheco's virus/ ... disease virus + newcastle disease virus/paramyxovirus QI01AD12 Avian pox virus QI01AD13 Avian leucosis virus QI01AD14 Avian ... disease virus + newcastle disease virus/paramyxovirus + avian rhinotracheitis virus QI01AA07 Avian infectious bronchitis virus ... avian herpes virus (Marek's disease) QI01AD16 Avian herpes virus (Marek's disease) + avian infectious bursal disease virus ( ...
Because of the virus' ability to rapidly respond to selective pressures imposed by the immune system, the population of virus ... Canarypox is the first candidate HIV vaccine that has induced cross-clade functional CTL responses. The first phase I trial of ... Some vaccines based on the virus envelope have protected chimpanzees or macaques from homologous virus challenge, but in ... using a genetically modified form of the HIV virus. The new method involves manipulating the virus' codons, this is a sequence ...
This allows the virus to theoretically carry 22 to 40 genes. Although this is significantly larger than other viruses in its ... such as Cytomegalovirus and Canarypox. By comparison, a Science's article reported that China had approved CanSino's Ebola ... Once the virus has successfully gained entry into the host cell, the endosome acidifies, which alters virus topology by causing ... Medicine portal Viruses portal VA (viral associated) RNA "9.11H: Double-Stranded DNA Viruses- Adenoviruses". Biology LibreTexts ...
Because of the virus's ability to rapidly respond to selective pressures imposed by the immune system, the population of virus ... The canarypox vector is the first candidate HIV vaccine that has induced cross-clade functional CTL responses. The first phase ... Because this amino acid is foreign to the human body, the virus cannot reproduce. Viruses portal Cabotegravir COVID-19 vaccine ... Some vaccines based on the virus envelope have protected chimpanzees or macaques from homologous virus challenge, but in ...
Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor α secretion ... Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC ... Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in ... Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in ...
The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC ... The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC ... The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC ... The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC ...
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J. Virol. 67:2370 ... Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet. Rec. 153:141-145. doi:10.1136/vr.153.5.141. ... A canarypox virus expressing the env and gag/pro genes of FeLV (ALVAC-FeLV) was shown to fully protect cats against persistent ... The canarypox virus per se has been shown to stimulate innate immunity, in particular the production of type I interferons, the ...
Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC ... EXPERIMENTAL DESIGN: The full-length Ep-CAM gene was inserted into the avipox virus ALVAC (ALVAC-KSA). Twelve radically ...
Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing ... Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer ... Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer ... We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC®) vaccine for ...
DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal ... uses a canarypox virus with.... Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With ... HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, ... Home » Topics » Vaccines » Research » Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV ...
... camelpox virus, AY009089.1; canarypox virus, NC005309.1; Cotia virus, KM595078.1; cowpox virus, DQ437593.1; deerpox virus, ... vaccinia virus, M35027.1; variola major virus, L22579.1; Yaba monkey tumor virus, NC005179.1; Yaba-like disease virus, ... goatpox virus, MH381810.1; lumpy skin disease virus, NC003027.1; monkeypox virus, DQ011157.1; myxoma virus, NC001132.2; rabbit ... fibroma virus, NC001266.1; sheeppox virus, NC004002.1; swinepox virus, NC003389.1; taterapox virus, NC008291.1; ...
Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) [ALVAC CEA] or a ... Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) [ALVAC CEA] or a ... Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With ... Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With ...
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies ... Serum IgG HIV-1-specific antibodies to rgp120 were rarely seen after either systemic or mucosal delivery of canarypox virus ... Over the course of 6 months, HIV-1-specific (vCP 205) and rabies (vCP 65) canarypox virus vectors were delivered systemically ... However, with the doses and routes of administration used, canarypox virus was not an effective mucosal immunogen. ...
Canarypox virus/genetics , Canarypox virus/growth & development , Canarypox virus/isolation & purification , Cell Line/virology ... Canarypox virus / Antigens, Viral Clinical aspect: Diagnosis Limits: Animals Language: Spanish Journal: Rev. argent. microbiol ... Animals , Chick Embryo , Cricetinae , Mice , Antigens, Viral/immunology , Canarypox virus/immunology , Glycoproteins/immunology ... SI bien estos sistemas no están disponibles comercialmente, la plataforma de obtención de virus canarypox (CNPV) recombinantes ...
... a lyophilized suspension of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus; ... a has been demonstrated to result in serum antibody titers that persist for at least 36 months against canine distemper virus ( ... housed in a CPV-2 disease-free environment where CAV-2 virus was known to be present, was conducted. Sentinel puppies were ... 3 Serologic testing that correlates with immunity by challenge studies include the serum virus neutralization (SVN) test for ...
Juncopox virus, Mynahpox virus, Psittacinepox virus, Sparrowpox virus, Starlingpox virus, Pigeonpox virus, Turkeypox virus and ... Canarypox virus (CNPV) is a member of the Poxviridae family. Canarypox viruses, as with other bird pox viruses, are in the ... Canarypox virus (CNPV) is an Avipoxvirus and etiologic agent of canarypox, a disease of wild and captive birds that can cause ... leukaemia virus, HIV and cancers; such as melanoma and colorectal cancers. A strain of canarypox virus modified to carry feline ...
... an adjuvanted killed virus noninfectious vaccine and a nonadjuvanted canarypox virus-vectored recombinant infectious vaccine ( ... Feline leukemia virus (FeLV) is an RNA virus in the subfamily Oncovirinae belonging to the Retroviridae family. The virus ... Merial produces a recombinant vaccine consisting of canarypox virus carrying FeLV gag and env genes (sold as PUREVAX FeLV in ... Once the virus has entered the cat, there are six stages to a FeLV infection[citation needed]: Stage One: The virus enters the ...
Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage ... Known Human Immunodeficiency Virus (HIV) infection or hepatitis B (Ag HBs) or hepatitis C seropositivity ...
Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol. 2007;179(9):6115-6122. ... Merkel cell carcinoma virus vaccine. The Merkel cell carcinoma virus was only recently identified as the cause of a rare, ... Human T lymphotrophic virus-1 vaccines. Human T lymphotrophic virus-1 (HTLV-1) is a retrovirus that causes adult T cell ... Antigens of choice in virus-induced cancers. Cancers caused by viruses and other infectious agents such as Helicobacter pylori ...
Canarypox virus CNPV Canarypox virus (CNPV) is an avipoxvirus and etiologic agent of canarypox, a disease of birds both in the ... Ustilago maydis Virus 4 (UmV4) 100342 Vaccinia virus Poxvirus Vaccinia virus is well known for its role as a vaccine (its ... Bovine viral diarrhea virus 2 BVDV-2 The virus genome is positive-strand RNA that is translated to form a single virus ... Cassava brown streak virus Cassava Brown Streak Virus Cassava brown streak virus is 650 nm long and has a genome that consists ...
Structural and Functional Insight into Canarypox Virus CNP058 Mediated Regulation of Apoptosis ... Viruses, EISSN 1999-4915, Published by MDPI AG Disclaimer The statements, opinions and data contained in the journal Viruses ... Journal: Viruses, 2017. Volume: 9 Number: 308 308 Article: Gammaherpesviral Tegument Proteins, PML-Nuclear Bodies and the ...
In this review, we discuss mechanisms and functional consequences of virus-induced ubiquitination and deubiquitination for ... Gammaherpesviruses like Epstein-Barr virus (EBV) and Kaposis sarcoma-associated herpesvirus (KSHV) subvert the ubiquitin ... Structural and Functional Insight into Canarypox Virus CNP058 Mediated Regulation of Apoptosis ... Viruses 2017, 9, 308. AMA Style. Full F, Hahn AS, Großkopf AK, Ensser A. Gammaherpesviral Tegument Proteins, PML-Nuclear Bodies ...
... consists of a weakened canarypox virus that has been genetically altered to contain a few selected HIV genes. The canarypox ... The vaccines contain only selected HIV genes or proteins, and not the whole virus, so an individual cannot become infected from ... For example, two newer canarypox HIV vaccines are undergoing a head-to-head evaluation. The current study adds compelling new ... virus cannot grow or cause disease in humans. SF-2 rgp120, made by Chiron (Emeryville, CA), is a genetically engineered copy of ...
... recombinant vaccinia virus; rF, recombinant fowlpox virus; TH, T helper; ALVAC, recombinant canarypox (avianpox) virus. ... influenza virus, avian influenza virus, or NDV) or cytokines known to promote T- and B-cell proliferation will activate innate ... Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to ... Studies are ongoing in an attempt to modify the Adv fibers so as to increase the infectivity of the virus in APCs. ...
FeLV recombinant canarypox virus (vCP97) ≥ 107.2 CCID501 1: cell culture infective dose 50% For the full list of excipients, ... Attenuated feline panleucopenia virus (PLI IV) ≥ 103.5 CCID501 Excipient: Gentamicin, at most 23 μg Solvent: Active substance: ...
Killed Virus, Live Canarypox Vector, Tetanus Toxoid contains a lyophilized recombinant canarypox vectored West Nile Virus (WNV ... Encephalomyelitis - West Nile Virus Vaccine, Eastern & Western, Killed Virus, Live Canarypox Vector, Tetanus Toxoid ... and Western Equine Encephalomyelitis virus (WEEV), and Clostridium tetani toxoid. A canarypox vector has been modified using ... and encephalitis caused by West Nile Virus and encephalitis caused by Eastern Equine Encephalomyelitis Virus (EEEV) and Western ...
The mosquito-transmitted pathogen West Nile virus (WNV) is not yet present in the Galápagos Archipelago of Ecuador. However, ... Characterization of canarypox-like viruses infecting endemic birds in the Galápagos Islands. J Wildl Dis 41: 342-353.[Crossref] ... West Nile virus: epidemiology and ecology in North America. Adv Virus Res 61: 185-234.[Crossref]. [Google Scholar] ... West Nile virus: an old virus learning new tricks? J Neurovirol 11: 469-475.[Crossref]. [Google Scholar] ...
... fowl pox virus, pigeon pox virus and canary pox virus. Although some workers include turkey pox virus as a distinct strain, ... I thought antibiotics did not help a virus...Is is just for the secondary respiratory infection? Is that not part of the virus ... Although the above article refers to the flu virus, most viruses react the same. The important thing is to remember that a ... Be sure the label specifically states that the product kills influenza virus, not just bacteria. A virus is not a bacteria. ...
In clinical trials, canarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV-specific ... High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.. Goepfert PA1, Horton H, ... Development of highly immunogenic canarypox vectors requires further work to optimize vector and insert design, as well as ...
The carrier virus (Merial uses canarypox) will multiply in the host, but wont cause disease in any way. Its similar in ... and patches it into a different virus, leaving out all the disease-causing bits of the rabies virus (or whatever disease the ... Since it doesnt contain any adjuvant (extra material to stimulate the immune system) like killed viruses do, its generally ... A recombinant vaccine takes the important bits of the virus that the immune system needs to recognize, ...
One candidate made from a canarypox virus that closely resembles vaccinia is in clinical trials. Canarypox virus does not grow ... Unlike most other viruses, HIV can be transmitted and can exist in the body not only as free virus but also in infected cells. ... There the virus can hide indefinitely until the cell receives an activation signal and makes new viruses. Other cells act as ... live-attenuated virus vaccine -- live HIV from which one or more apparent disease-promoting genes of the virus have been ...
The prime vaccine, ALVAC, consisted of HIV genes contained in a canarypox virus vector. This model of vaccine delivery was ... we know a sufficiently large innoculum of virus can overcome any vaccine-generated response." ... a breakthrough strategy is finally offering fresh tools for battling this devastating virus. ...
  • Canarypox virus (CNPV) is an Avipoxvirus and etiologic agent of canarypox, a disease of wild and captive birds that can cause significant losses. (wikipedia.org)
  • Generally CNPV is considered a disease of songbirds, such as canaries, magpies and nightingales, and is associated with higher mortality rates when compared to other avian pox viruses. (wikipedia.org)
  • As the disease progresses blisters get progressively larger and form nodules where the virus can multiply. (wikipedia.org)
  • The general symptoms of CNPV are similar to those of other species of avian pox viruses and are characterised by pustules and diphtheria or pneumonia-like symptoms. (wikipedia.org)
  • Experiment outside containment (clinical trial) for the study of the safety of a sucutaneous administration of a recombinant canarypoxvirus expressing FELV genes. (biosafety.be)
  • The introduction of vaccines against bluetongue pathogen (BTV), the causative agent of BT, includes a background reaching back again to early South African live attenuated vaccines and increasing forwards to next-generation styles involving the usage of more-advanced adjuvants and brand-new vaccine types, such as for example virus-like particle, subunit, impaired infectious single-cycle, or recombinant vector vaccines (as evaluated by Roy et al. (tas-102.net)
  • Calvenza provides protection against Equine Influenza and Equine Herpes viruses 1 in a single vaccine as required by the US Equestrian Federation, the Hong Kong Jockey Club and the French Racing Association among others. (rockmediaconsulting.com)
  • Canarypox construct vaccine to protect horses and foals from 5 months of age against West Nile encephalitis. (rockmediaconsulting.com)
  • In 1932-3 Burnet took leave of absence from WEHI to hold a fellowship at the National Institute for Medical Research in Hampstead, London, where he witnessed what can now be seen as a 'golden age' of virology, including the isolation of the influenza virus and its transmission to ferrets. (immunology.org.au)
  • Influenza and Herpes are the most frequent respiratory viruses that affect horses. (rockmediaconsulting.com)
  • A major contribution at this time was his demonstration that canary pox virus (and by implication, other viruses) could be quantitated by making serial dilutions and counting pocks on the chorioallantoic membrane of embryonated eggs. (immunology.org.au)
  • The virus has been introduced to several remote islands such as Hawaii, and the Canary Islands where it spreads rapidly among the native bird populations, avian pox has negatively impacted many species of native birds! (priysoft.com)
  • The virus exits the host feeds on a bird in dry mucous membranes of an in the bloodstream or feeds. (priysoft.com)